Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
Study Finds on MSN
FDA-cleared brain stimulation device for ADHD works no better than placebo in major trial
In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, new research finds that this is not the case.
Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...
12d
Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...
Do you suspect you or your loved ones have ADHD? Are you struggling with attention, focus, or hyperactivity? Are your symptoms starting to negatively impact your performance at school, work or even in ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback